We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+18.92%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$598M
AUM Growth
+$132M
Cap. Flow
+$140M
Cap. Flow %
23.32%
Top 10 Hldgs %
44.39%
Holding
102
New
38
Increased
16
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$24.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.2M
3
MSFT icon
Microsoft
MSFT
+$13.9M
4
NTR icon
Nutrien
NTR
+$11.2M
5
AMZN icon
Amazon
AMZN
+$8.28M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.9M
2
ALBO
Albireo Pharma Inc
ALBO
+$10M
3
AZN icon
AstraZeneca
AZN
+$7.74M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$6.51M
5
KROS icon
Keros Therapeutics
KROS
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 59.53%
2 Technology 8.91%
3 Materials 1.8%
4 Consumer Discretionary 1.48%
5 Utilities 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
51
CALL
uniQure
QURE
$3.03B
$3.53M 0.59%
+175,400
New +$3.68M
PCVX icon
52
Vaxcyte
PCVX
$7.81B
$3.37M 0.56%
+90,000
New +$3.82M
BBIO icon
53
CALL
BridgeBio Pharma
BBIO
$15.7B
$3.32M 0.55%
+200,000
New +$2.33M
COGT icon
54
Cogent Biosciences
COGT
$6.65B
$3.24M 0.54%
+300,000
New +$3.84M
RNAC icon
55
Cartesian Therapeutics
RNAC
$229M
$3.23M 0.54%
+77,500
New +$3.64M
MIRM icon
56
Mirum Pharmaceuticals
MIRM
$6.46B
$2.63M 0.44%
+109,336
New +$2.49M
DYN icon
57
Dyne Therapeutics
DYN
$4.7B
$2.53M 0.42%
219,316
+212,167
+2,968% +$2.76M
RIGL icon
58
Rigel Pharmaceuticals
RIGL
$681M
$2.48M 0.41%
187,885
-40,000
-18% -$635K
AMGN icon
59
Amgen
AMGN
$208B
$2.42M 0.4%
+10,000
New +$2.45M
RZLT icon
60
Rezolute
RZLT
$454M
$2.22M 0.37%
1,155,897
– –
KDNY
61
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.13M 0.36%
92,200
-35,000
-28% -$834K
HOWL icon
62
Werewolf Therapeutics
HOWL
$17.2M
$1.63M 0.27%
626,810
– –
ALPN
63
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.54M 0.26%
200,000
– –
MDWD icon
64
MediWound
MDWD
$181M
$1.48M 0.25%
111,127
+35,714
+47% +$450K
CRNX icon
65
Crinetics Pharmaceuticals
CRNX
$8.84B
$1.33M 0.22%
82,747
-588,897
-88% -$10.9M
KROS icon
66
Keros Therapeutics
KROS
$199M
$1.29M 0.21%
30,119
-128,638
-81% -$6.5M
ALT icon
67
Altimmune
ALT
$552M
$1.27M 0.21%
300,000
-80,298
-21% -$954K
QURE icon
68
uniQure
QURE
$3.03B
$1.25M 0.21%
+62,000
New +$1.3M
ANNX icon
69
Annexon
ANNX
$834M
$963K 0.16%
+250,000
New +$1.38M
PMVP icon
70
PMV Pharmaceuticals
PMVP
$59.2M
$896K 0.15%
187,800
– –
RETA
71
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$699K 0.12%
+7,689
New +$451K
INFI
72
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$236K 0.04%
1,476,000
– –
SYRE icon
73
Spyre Therapeutics
SYRE
$8.54B
$187K 0.03%
25,859
+8,226
+47% +$90.2K
OTMO
74
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
$186K 0.03%
26,124
– –
ONCR
75
DELISTED
Oncorus, Inc.
ONCR
$186K 0.03%
540,258
– –
1 2
3
4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2023 Portfolio in Review

As of Q1 2023, Sphera Funds Management held 102 positions worth $598M, up 28% from $466M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management deployed $140M of net new capital in Q1 2023, opening 38 new positions and adding to 16 existing holdings. Its largest new stake was Nice: 115,482 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 60% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $10.9M trimmed.

  • Sphera Funds Management's largest Q1 2023 buy was Nice: 115,482 shares worth $26.4M.
  • Sphera Funds Management added most to Biogen in Q1 2023, an estimated $7.19M increase.
  • Sphera Funds Management's biggest Q1 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.9M.
  • Sphera Funds Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $598M portfolio in Q1 2023.
  • Sphera Funds Management opened 38 new positions and closed 21 in Q1 2023.
  • Sphera Funds Management's portfolio value rose 28% quarter-over-quarter to $598M.

Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.